DVAX Dynavax Technologies Corporation

20.50
-0.30  -1%
Previous Close 20.80
Open 20.80
Price To book 8.84
Market Cap 1240201948
Shares 60,497,656
Volume 918,797
Short Ratio 2.59
Av. Daily Volume 3,160,761

SEC filingsSee all SEC filings

  1. 8-K - Current report 171066392
  2. 8-K - Current report 171021660
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171021632
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171018454
  5. 424B5 - Prospectus [Rule 424(b)(5)] 171014898

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 1Q 2017.
SD-101
Head and neck squamous-cell carcinoma cancer
Noted June 2 ORR of 7/7 in anti-PD-1/L1-naïve patients.
SD-101 + Pembrolizumab
Melanoma - cancer
Phase 1/2 data presented at ASH 2016.
SD-101
Low-grade, B cell lymphoma
CRL February 25, 2013 and November 14, 2016. Original PDUFA date set for August 10, 2017 but noted August 3, 2017 a 3-month extension to August 10.. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval.
HEPLISAV-B
Hepatitis B
Phase 2 enrolling as of early 2017.
AZD1419
Asthma

SEC Filings

  1. 8-K - Current report 171066392
  2. 8-K - Current report 171021660
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171021632
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171018454
  5. 424B5 - Prospectus [Rule 424(b)(5)] 171014898
  6. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 171014657
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011729
  8. 8-K - Current report 171011478
  9. 8-K - Current report 17999950
  10. 8-K - Current report 17993308